Biotech's rebound and what's next

Thursday, June 25, 2026  |  12:00 PM – 1:00 PM ET

A year ago, our Endpoints 100 survey captured one of the bleakest moments for biotech in a decade. The IPO market was frozen, venture funding had cratered, and execs were bracing for disruption as the FDA underwent a major overhaul.

Now? Biotech is in a very different place. IPOs are rebounding, China deals are heating up, and sentiment in the c-suite has improved.

But FDA leadership has churned again, and execs are weighing a new set of challenges. Join Editor-in-Chief John Carroll and a panel of industry leaders as they dig into the latest E100 results and what they reveal about where the industry is headed.